Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - September 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Denosumab (Prolia®) has been rejected for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - September 2018' on Email Share 'SMC Update - September 2018' on Delicious Share 'SMC Update - September 2018' on Digg Share 'SMC Update - September 2018' on Facebook Share 'SMC Update - September 2018' on Google+ Share 'SMC Update - September 2018' on reddit Share 'SMC Update - September 2018' on StumbleUpon Share 'SMC Update - September 2018' on Twitter

atomic-wealth

No Comments to “SMC Update - September 2018”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer